Methods of Preparing Cannabinoids From Plant Material
AssigneeGW Pharma Limited
InventorsIan Flockhart, Gary William Wheatley, Su Dring, Leslie Archer
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.
Claims91
A method of obtaining a substantially pure cannabinoid or cannabinoid acid or a product enriched in a given cannabinoid or cannabinoid acid from a plant material, comprising:
- i) obtaining an extract containing a cannabinoid or cannabinoid acid from a plant material;
- ii) subjecting the extract of step (i) to a chromatographic step to produce a partially purified extract;
- iii) dissolving the partially purified extract in a first solvent, removing any insoluble material therefrom and removing the solvent;
- and
- iv) dissolving the product obtained in step iii) in a second solvent, removing any insoluble material therefrom, and removing the solvent to obtain the substantially pure cannabinoid or cannabinoid acid or the product enriched in a given cannabinoid or cannabinoid acid, wherein the first and second solvents are different, and wherein one of the first or second solvents is a solvent which is substantially more polar than the cannabinoid/cannabinoid acid which it is desired to purify, and the other solvent is a solvent which is substantially less polar than the cannabinoid/cannabinoid acid which it is desired to purify.
A method according to any one of the preceding claims wherein the extract containing a cannabinoid or cannabinoid acid obtained in step (i) is prepared by a process comprising solvent extraction of the plant material.
A method according to any one of the preceding claims wherein the chromatographic step comprises column chromatography.
A method according to any one of the preceding claims wherein the chromatographic step is based on molecular sizing and polarity.
A substantially pure preparation of Δ9 tetrahydrocannabinolic acid (Δ9 THCA) having a chromatographic purity of greater than 95%, more preferably greater than 96%, more preferably greater than 97% or most preferably greater than 98% by area normalisation of an HPLC profile.
A substantially pure preparation of Δ9 tetrahydrocannabinolic acid (Δ9 THCA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 2.
A substantially pure preparation of cannabidiolic acid (CBDA) having a chromatographic purity of greater than 90%, more preferably greater than 92% or most preferably greater than 94% by area normalisation of an HPLC profile.
A substantially pure preparation of cannabidiolic acid (CBDA) having a chromatographic purity of greater than 94%, more preferably greater than 96% or most preferably greater than 98% by area normalisation of an HPLC profile.
A substantially pure preparation of cannabidiolic acid (CBDA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 4.
A substantially pure preparation of cannabidiolic acid (CBDA) substantially as described herein and having an HPLC profile substantially as shown in FIG. 5.
A substantially pure preparation of Δ9 tetrahydrocannabinol (Δ9 THC) having a chromatographic purity of >99% by area normalisation of an HPLC profile.
A substantially pure preparation of Δ9 tetrahydrocannabinol (Δ9 THC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 8.
A substantially pure preparation of Δ9 tetrahydrocannabivarin (Δ9 THCV) having a chromatographic purity of greater than 95%, more preferable greater than 96%, more preferable greater than 97%, more preferable greater than 98%, and most preferable greater than 99% by area normalisation of an HPLC profile.
A substantially pure preparation of Δ9 tetrahydrocannabivarin (Δ9 THCV) substantially as described herein and having an HPLC profile substantially as shown in FIG. 11.
A product enriched in cannabigerol (CBG) having a chromatographic purity of greater than 90%, preferably greater than 92% by area normalisation of an HPLC profile.
A substantially pure preparation of cannabigerol (CBG) having a chromatographic purity of greater than 92%, more preferably greater than 94%, more preferably greater than 96% or most preferably greater than 97% by area normalisation of an HPLC profile.
A product enriched in cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 14.
A substantially pure preparation of cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 15.
A substantially pure preparation of cannabigerol (CBG) substantially as described herein and having an HPLC profile substantially as shown in FIG. 16.
A product enriched in cannabichromene (CBC) having a chromatographic purity of greater than 80%, more preferably greater than 85% by area normalisation of an HPLC profile.
A substantially pure preparation of cannabichromene (CBC) having a chromatographic purity of greater than 85%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 98% or most preferably greater than 99% by area normalisation of an HPLC profile.
A product enriched in cannabichromene (CBC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 19.
A substantially pure preparation of cannabichromene (CBC) substantially as described herein and having an HPLC profile substantially as shown in FIG. 20.
Dependencies are inferred from the claim text.